{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:18:56Z","timestamp":1792783136354,"version":"4.5.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T00:00:00Z","timestamp":1571875200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T00:00:00Z","timestamp":1571875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"DOD","award":["W81XWH1810802"],"award-info":[{"award-number":["W81XWH1810802"]}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21AI131241"],"award-info":[{"award-number":["R21AI131241"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["1UL1TR001111"],"award-info":[{"award-number":["1UL1TR001111"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011485","name":"NC TraCS","doi-asserted-by":"crossref","award":["4DR31502"],"award-info":[{"award-number":["4DR31502"]}],"id":[{"id":"10.13039\/100011485","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006392","name":"AIDS Clinical Trials Group","doi-asserted-by":"crossref","award":["AI068636"],"award-info":[{"award-number":["AI068636"]}],"id":[{"id":"10.13039\/100006392","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s11095-019-2704-6","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T13:13:57Z","timestamp":1572009237000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Why Wait? The Case for Treating Tuberculosis with Inhaled Drugs"],"prefix":"10.1007","volume":"36","author":[{"given":"Miriam","family":"Braunstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Hickey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5691-5790","authenticated-orcid":false,"given":"Sean","family":"Ekins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,24]]},"reference":[{"key":"2704_CR1","unstructured":"WHO. Global tuberculosis report 2018. World Health Organization. Available from: \nhttps:\/\/www.who.int\/tb\/publications\/global_report\/en\/\n\n."},{"key":"2704_CR2","doi-asserted-by":"crossref","unstructured":"Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, Nardell EA, London L, Lessem E, Theron G, van Helden P, Niemann S, Merker M, Dowdy D, Van Rie A, Siu GK, Pasipanodya JG, Rodrigues C, Clark TG, Sirgel FA, Esmail A, Lin HH, Atre SR, Schaaf HS, Chang KC, Lange C, Nahid P, Udwadia ZF, Horsburgh CR, Jr., Churchyard GJ, Menzies D, Hesseling AC, Nuermberger E, McIlleron H, Fennelly KP, Goemaere E, Jaramillo E, Low M, Jara CM, Padayatchi N, Warren RM. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med. 2017.","DOI":"10.1016\/S2213-2600(17)30079-6"},{"issue":"9","key":"2704_CR3","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S2213-2600(19)30263-2","volume":"7","author":"K Dheda","year":"2019","unstructured":"Dheda K, Gumbo T, Maartens G, Dooley KE, Murray M, Furin J, et al. Lancet respiratory medicine drug-resistant tuberculosis commission g. the lancet respiratory medicine commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. Lancet Respir Med. 2019;7(9):820\u20136.","journal-title":"Lancet Respir Med"},{"key":"2704_CR4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/B978-0-12-405880-4.00009-3","volume":"67","author":"E De Clercq","year":"2013","unstructured":"De Clercq E. The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS). Adv Pharmacol. 2013;67:317\u201358.","journal-title":"Adv Pharmacol"},{"key":"2704_CR5","unstructured":"Hickey AJ, Montgomery AB. Aerosolized pentamidine for treatment and prophylaxis of Pneumocystis carinii pneumonia with acquired immunodeficiency syndrome. In: Hickey AJ, editor. Pharmaceutical inhalation aerosol technology: Marcel Dekker; 2004; 459\u2013488."},{"issue":"7","key":"2704_CR6","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.21037\/jtd.2017.06.16","volume":"9","author":"L D'Ambrosio","year":"2017","unstructured":"D'Ambrosio L, Centis R, Tiberi S, Tadolini M, Dalcolmo M, Rendon A, et al. Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review. J Thorac Dis. 2017;9(7):2093\u2013101.","journal-title":"J Thorac Dis"},{"issue":"7","key":"2704_CR7","doi-asserted-by":"crossref","first-page":"e1000423","DOI":"10.1371\/journal.pcbi.1000423","volume":"5","author":"SL Kinnings","year":"2009","unstructured":"Kinnings SL, Liu N, Buchmeier N, Tonge PJ, Xie L, Bourne PE. Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis. PLoS Comput Biol. 2009;5(7):e1000423.","journal-title":"PLoS Comput Biol"},{"key":"2704_CR8","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.tube.2018.08.004","volume":"112","author":"G Mori","year":"2018","unstructured":"Mori G, Orena BS, Franch C, Mitchenall LA, Godbol AA, Rodrigues L, et al. The EU approved antimalarial Pyronaridine shows Antitubercular activity and synergy with rifampicin, targeting RNA polymerase. Tuberculosis. 2018;112:98\u2013109.","journal-title":"Tuberculosis"},{"key":"2704_CR9","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.drudis.2016.09.025","volume":"22","author":"K Mikusova","year":"2017","unstructured":"Mikusova K, Ekins S. Learning from the past for TB drug discovery in the future. Drug Discov Today. 2017;22:534\u201345.","journal-title":"Drug Discov Today"},{"key":"2704_CR10","unstructured":"NIAID. NIAID Startegic plan for tuberculosis research Available from: \nhttps:\/\/www.niaid.nih.gov\/sites\/default\/files\/TBStrategicPlan2018.pdf\n\n."},{"issue":"2","key":"2704_CR11","first-page":"207","volume":"80","author":"JB Miller","year":"1950","unstructured":"Miller JB, Abramson HA, Ratner B. Aerosol streptomycin treatment of advanced pulmonary tuberculosis in children. Am J Diseases Children. 1950;80(2):207\u201337.","journal-title":"Am J Diseases Children"},{"issue":"3","key":"2704_CR12","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/03639045.2016.1272119","volume":"43","author":"S Giovagnoli","year":"2017","unstructured":"Giovagnoli S, Schoubben A, Ricci M. The long and winding road to inhaled TB therapy: not only the bug's fault. Drug Dev Ind Pharm. 2017;43(3):347\u201363.","journal-title":"Drug Dev Ind Pharm"},{"key":"2704_CR13","doi-asserted-by":"crossref","unstructured":"Smaldone GC. Repurposing of gamma interferon via inhalation delivery. Adv Drug Deliv Rev 2018.","DOI":"10.1016\/j.addr.2018.06.004"},{"key":"2704_CR14","doi-asserted-by":"crossref","unstructured":"Newman SP. Delivering drugs to the lungs: the history of repurposing in the treatment of respiratory diseases. Adv Drug Deliv Rev 2018.","DOI":"10.1016\/j.addr.2018.04.010"},{"key":"2704_CR15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nrmicro3200","volume":"12","author":"V Dartois","year":"2014","unstructured":"Dartois V. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nat Rev Microbiol. 2014;12:159\u201367.","journal-title":"Nat Rev Microbiol"},{"issue":"12","key":"2704_CR16","doi-asserted-by":"crossref","first-page":"7331","DOI":"10.1128\/AAC.03510-14","volume":"58","author":"M Boisson","year":"2014","unstructured":"Boisson M, Jacobs M, Gregoire N, Gobin P, Marchand S, Couet W, et al. Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients. Antimicrob Agents Chemother. 2014;58(12):7331\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2704_CR17","doi-asserted-by":"crossref","first-page":"e1002773","DOI":"10.1371\/journal.pmed.1002773","volume":"16","author":"N Strydom","year":"2019","unstructured":"Strydom N, Gupta SV, Fox WS, Via LE, Bang H, Lee M, et al. Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: a mechanistic model and tool for regimen and dose optimization. PLoS Med. 2019;16(4):e1002773.","journal-title":"PLoS Med"},{"issue":"9","key":"2704_CR18","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1164\/rccm.201711-2333OC","volume":"198","author":"K Dheda","year":"2018","unstructured":"Dheda K, Lenders L, Magombedze G, Srivastava S, Raj P, Arning E, et al. Drug-penetration gradients associated with acquired drug resistance in patients with tuberculosis. Am J Respir Crit Care Med. 2018;198(9):1208\u201319.","journal-title":"Am J Respir Crit Care Med"},{"key":"2704_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/9781118943182","volume-title":"Drug delivery systems for tuberculosis prevention and treatment","author":"AJ Hickey","year":"2016","unstructured":"Hickey AJ. Introduction: A guide to treatment and prevention of tuberculosis based on principles of dosage form design and drug delivery. In: Hickey AJ, Misra A, Fourie PB, editors. Drug delivery systems for tuberculosis prevention and treatment. New York: John Wiley and Sons; 2016. p. 1\u201310."},{"key":"2704_CR20","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jconrel.2015.11.018","volume":"240","author":"AJ Hickey","year":"2016","unstructured":"Hickey AJ, Durham PG, Dharmadhikari A, Nardell EA. Inhaled drug treatment for tuberculosis: past progress and future prospects. J Control Release : Off J Control Release Soc. 2016;240:127\u201334.","journal-title":"J Control Release : Off J Control Release Soc"},{"issue":"11","key":"2704_CR21","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.5588\/ijtld.17.0468","volume":"21","author":"A Reuter","year":"2017","unstructured":"Reuter A, Tisile P, von Delft D, Cox H, Cox V, Ditiu L, et al. The devil we know: is the use of injectable agents for the treatment of MDR-TB justified? Int J Tuberc Lung Dis. 2017;21(11):1114\u201326.","journal-title":"Int J Tuberc Lung Dis."},{"issue":"4","key":"2704_CR22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1089\/jamp.2010.0855","volume":"24","author":"DE Geller","year":"2011","unstructured":"Geller DE, Weers J, Heuerding S. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere technology. J Aerosol Med Pulm Drug Deliv. 2011;24(4):175\u201382.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"5","key":"2704_CR23","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jcf.2012.03.010","volume":"11","author":"KJ Littlewood","year":"2012","unstructured":"Littlewood KJ, Higashi K, Jansen JP, Capkun-Niggli G, Balp MM, Doering G, et al. Angyalosi G. a network meta-analysis of the efficacy of inhaled antibiotics for chronic pseudomonas infections in cystic fibrosis. J Cystic Fibrosis : Off J Eur Cystic Fibrosis Soc. 2012;11(5):419\u201326.","journal-title":"J Cystic Fibrosis : Off J Eur Cystic Fibrosis Soc"},{"key":"2704_CR24","unstructured":"GINA. Global Initiative for Asthma Main Report; 2019. Available from: \nhttps:\/\/ginasthma.org\/wp-content\/uploads\/2019\/06\/GINA-2019-main-report-June-2019-wms.pdf\n\n."},{"key":"2704_CR25","unstructured":"GOLD. Global Initiative for Chronic Obstructive Lung Disease; 2019. Available from: \nhttps:\/\/goldcopd.org\/wp-content\/uploads\/2018\/11\/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf\n\n."},{"issue":"1\u20132","key":"2704_CR26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ijpharm.2006.11.021","volume":"335","author":"EM Westerman","year":"2007","unstructured":"Westerman EM, de Boer AH, Le Brun PP, Touw DJ, Frijlink HW, Heijerman HG. Dry powder inhalation of colistin sulphomethate in healthy volunteers: a pilot study. Int J Pharm. 2007;335(1\u20132):41\u20135.","journal-title":"Int J Pharm"},{"issue":"4","key":"2704_CR27","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jcf.2006.10.010","volume":"6","author":"EM Westerman","year":"2007","unstructured":"Westerman EM, De Boer AH, Le Brun PP, Touw DJ, Roldaan AC, Frijlink HW, et al. Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study. J Cystic Fibrosis : Off J Eur Cystic Fibrosis Soc. 2007;6(4):284\u201392.","journal-title":"J Cystic Fibrosis : Off J Eur Cystic Fibrosis Soc."},{"issue":"3","key":"2704_CR28","doi-asserted-by":"crossref","first-page":"1702490","DOI":"10.1183\/13993003.02490-2017","volume":"51","author":"Onno W. Akkerman","year":"2018","unstructured":"Akkerman OW, Grasmeijer F, de Lange WCM, Kerstjens HAM, de Vries G, Bolhuis MS, Alffenaar JW, Frijlink HW, Smith G, Gajraj R, de Zwaan R, Hagedoorn P, Dedicoat M, van Soolingen D, van der Werf TS. Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis. Eur Respir J. 2018;51(3).","journal-title":"European Respiratory Journal"},{"issue":"7","key":"2704_CR29","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1128\/AAC.00464-12","volume":"56","author":"M Gonzalez-Juarrero","year":"2012","unstructured":"Gonzalez-Juarrero M, Woolhiser LK, Brooks E, DeGroote MA, Lenaerts AJ. Mouse model for efficacy testing of antituberculosis agents via intrapulmonary delivery. Antimicrob Agents Chemother. 2012;56(7):3957\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"2704_CR30","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1128\/AAC.01164-06","volume":"51","author":"L Garcia-Contreras","year":"2007","unstructured":"Garcia-Contreras L, Fiegel J, Telko MJ, Elbert K, Hawi A, Thomas M, et al. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a Guinea pig model. Antimicrob Agents Chemother. 2007;51(8):2830\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2704_CR31","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1128\/AAC.02346-12","volume":"57","author":"AS Dharmadhikari","year":"2013","unstructured":"Dharmadhikari AS, Kabadi M, Gerety B, Hickey AJ, Fourie PB, Nardell E, et al. Single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis. Antimicrob Agents Chemother. 2013;57(6):2613\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2704_CR32","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.201604-0700OC","volume":"195","author":"KN Olivier","year":"2017","unstructured":"Olivier KN, Griffith DE, Eagle G, McGinnis JP 2nd, Micioni L, Liu K, et al. Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease. Am J Respir Crit Care Med. 2017;195(6):814\u201323.","journal-title":"Am J Respir Crit Care Med"},{"key":"2704_CR33","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2466-7-2","volume":"7","author":"KK Davis","year":"2007","unstructured":"Davis KK, Kao PN, Jacobs SS, Ruoss SJ. Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series. BMC Pulm Med. 2007;7:2.","journal-title":"BMC Pulm Med"},{"issue":"8","key":"2704_CR34","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1007\/s10096-011-1516-3","volume":"31","author":"A Safdar","year":"2012","unstructured":"Safdar A. Aerosolized amikacin in patients with difficult-to-treat pulmonary nontuberculous mycobacteriosis. Eur J Clin Microbiol Infect Dis. 2012;31(8):1883\u20137.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"2704_CR35","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1186\/s12879-017-2665-5","volume":"17","author":"K Yagi","year":"2017","unstructured":"Yagi K, Ishii M, Namkoong H, Asami T, Iketani O, Asakura T, et al. The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases. BMC Infect Dis. 2017;17(1):558.","journal-title":"BMC Infect Dis"},{"issue":"8","key":"2704_CR36","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1086\/322725","volume":"33","author":"P Parola","year":"2001","unstructured":"Parola P, Brouqui P. Clinical and microbiological efficacy of adjunctive salvage therapy with inhaled aminoglycosides in a patient with refractory cavitary pulmonary tuberculosis. Clin Infect Dis. 2001;33(8):1439.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2704_CR37","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1086\/317524","volume":"32","author":"LV Sacks","year":"2001","unstructured":"Sacks LV, Pendle S, Orlovic D, Andre M, Popara M, Moore G, et al. Adjunctive salvage therapy with inhaled aminoglycosides for patients with persistent smear-positive pulmonary tuberculosis. Clin Infect Dis. 2001;32(1):44\u20139.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"2704_CR38","first-page":"769","volume":"5","author":"T Rikimaru","year":"2001","unstructured":"Rikimaru T, Koga T, Sueyasu Y, Ide S, Kinosita M, Sugihara E, et al. Treatment of ulcerative endobronchial tuberculosis and bronchial stenosis with aerosolized streptomycin and steroids. Int J Tuberc Lung Dis. 2001;5(8):769\u201374.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"10","key":"2704_CR39","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1007\/s11095-016-1974-5","volume":"33","author":"EF Young","year":"2016","unstructured":"Young EF, Perkowski E, Malik S, Hayden JD, Durham PG, Zhong L, et al. Inhaled Pyrazinoic acid esters for the treatment of tuberculosis. Pharm Res. 2016;33(10):2495\u2013505.","journal-title":"Pharm Res"},{"issue":"9","key":"2704_CR40","doi-asserted-by":"crossref","first-page":"e0204495","DOI":"10.1371\/journal.pone.0204495","volume":"13","author":"SA Montgomery","year":"2018","unstructured":"Montgomery SA, Young EF, Durham PG, Zulauf KE, Rank L, Miller BK, et al. Efficacy of pyrazinoic acid dry powder aerosols in resolving necrotic and non-necrotic granulomas in a Guinea pig model of tuberculosis. PLoS One. 2018;13(9):e0204495.","journal-title":"PLoS One"},{"issue":"2","key":"2704_CR41","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/nm.3458","volume":"20","author":"Richard E Lee","year":"2014","unstructured":"Lee RE, Hurdle JG, Liu J, Bruhn DF, Matt T, Scherman MS, Vaddady PK, Zheng Z, Qi J, Akbergenov R, Das S, Madhura DB, Rathi C, Trivedi A, Villellas C, Lee RB, Rakesh, Waidyarachchi SL, sun D, McNeil MR, Ainsa JA, Boshoff HI, Gonzalez-Juarrero M, Meibohm B, Bottger EC, Lenaerts AJ. Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux. Nat Med 2014;20(2):152\u2013158.","journal-title":"Nature Medicine"},{"issue":"8","key":"2704_CR42","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1023\/A:1007527204887","volume":"17","author":"P O'Hara","year":"2000","unstructured":"O'Hara P, Hickey AJ. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization. Pharm Res. 2000;17(8):955\u201361.","journal-title":"Pharm Res"},{"issue":"9","key":"2704_CR43","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1023\/A:1013094112861","volume":"18","author":"S Suarez","year":"2001","unstructured":"Suarez S, O'Hara P, Kazantseva M, Newcomer CE, Hopfer R, McMurray DN, et al. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model. Pharm Res. 2001;18(9):1315\u20139.","journal-title":"Pharm Res"},{"issue":"3","key":"2704_CR44","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/jac\/48.3.431","volume":"48","author":"S Suarez","year":"2001","unstructured":"Suarez S, O'Hara P, Kazantseva M, Newcomer CE, Hopfer R, McMurray DN, et al. Airways delivery of rifampicin microparticles for the treatment of tuberculosis. J Antimicrob Chemother. 2001;48(3):431\u20134.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"2704_CR45","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1128\/AAC.01897-12","volume":"57","author":"RK Verma","year":"2013","unstructured":"Verma RK, Germishuizen WA, Motheo MP, Agrawal AK, Singh AK, Mohan M, et al. Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice. Antimicrob Agents Chemother. 2013;57(2):1050\u20132.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"2704_CR46","first-page":"873","volume":"74","author":"S Yokota","year":"1999","unstructured":"Yokota S, Miki K. Effects of INH (isoniazid) inhalation in patients with endobronchial tuberculosis (EBTB). Kekkaku. 1999;74(12):873\u20137.","journal-title":"Kekkaku."},{"issue":"4","key":"2704_CR47","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1128\/AAC.01471-09","volume":"54","author":"L Garcia-Contreras","year":"2010","unstructured":"Garcia-Contreras L, Sung JC, Muttil P, Padilla D, Telko M, Verberkmoes JL, et al. Dry powder PA-824 aerosols for treatment of tuberculosis in Guinea pigs. Antimicrob Agents Chemother. 2010;54(4):1436\u201342.","journal-title":"Antimicrob Agents Chemother"},{"key":"2704_CR48","doi-asserted-by":"crossref","unstructured":"Young EF, Hickey AJ, Braunstein M. Testing inhaled drug therapies for treating tuberculosis. In: Hickey AJ, editor. Delivery systems for tuberculosis prevention and treatment (advances in pharmaceutical technology): John Wiley and Sons, ltd. ; 2016. p. 113\u2013130.","DOI":"10.1002\/9781118943182.ch6"},{"issue":"11","key":"2704_CR49","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1007\/s11095-009-9957-4","volume":"26","author":"P Muttil","year":"2009","unstructured":"Muttil P, Wang C, Hickey AJ. Inhaled drug delivery for tuberculosis therapy. Pharm Res. 2009;26(11):2401\u201316.","journal-title":"Pharm Res"},{"issue":"6","key":"2704_CR50","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.smim.2014.09.009","volume":"26","author":"IM Orme","year":"2014","unstructured":"Orme IM, Basaraba RJ. The formation of the granuloma in tuberculosis infection. Semin Immunol. 2014;26(6):601\u20139.","journal-title":"Semin Immunol"},{"key":"2704_CR51","first-page":"324","volume":"58","author":"DJ Padilla-Carlin","year":"2008","unstructured":"Padilla-Carlin DJ, Mcmurray DN, Hickey A. The Guinea pig as a model of infectious diseases. Comparative Med. 2008;58:324\u201340.","journal-title":"Comparative Med"},{"issue":"3","key":"2704_CR52","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S1471-4892(03)00045-6","volume":"3","author":"BJ Canning","year":"2003","unstructured":"Canning BJ. Modeling asthma and COPD in animals: a pointless exercise? Curr Opin Pharmacol. 2003;3(3):244\u201350.","journal-title":"Curr Opin Pharmacol"},{"issue":"5","key":"2704_CR53","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.pupt.2008.01.004","volume":"21","author":"BJ Canning","year":"2008","unstructured":"Canning BJ, Chou Y. Using Guinea pigs in studies relevant to asthma and COPD. Pulm Pharmacol Ther. 2008;21(5):702\u201320.","journal-title":"Pulm Pharmacol Ther"},{"issue":"8","key":"2704_CR54","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1128\/AAC.01164-06","volume":"51","author":"L Garcia-Contreras","year":"2007","unstructured":"Garcia-Contreras L, Fiegel J, Telko MJ, Elbert K, Hawi A, Thomas M, et al. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a Guinea pig model. Antimicrob Agents Chemother. 2007;51(8):2830\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2704_CR55","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/jac\/dkl369","volume":"58","author":"L Garcia-Contreras","year":"2006","unstructured":"Garcia-Contreras L, Sethuraman V, Kazantseva M, Godfrey V, Hickey AJ. Evaluation of dosing regimen of respirable rifampicin biodegradable microspheres in the treatment of tuberculosis in the Guinea pig. J Antimicrob Chemother. 2006;58(5):980\u20136.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"2704_CR56","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.ijpharm.2016.04.063","volume":"514","author":"PG Durham","year":"2016","unstructured":"Durham PG, Young EF, Braunstein MS, Welch JT. Hickey AJ. A dry powder combination of pyrazinoic acid and its n-propyl ester for aerosol administration to animals. Int J Pharm. 2016;514(2):384\u201391.","journal-title":"Int J Pharm"},{"issue":"7","key":"2704_CR57","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1021\/jm00085a007","volume":"35","author":"MH Cynamon","year":"1992","unstructured":"Cynamon MH, Klemens SP, Chou TS, Gimi RH, Welch JT. Antimycobacterial activity of a series of pyrazinoic acid esters. J Med Chem. 1992;35(7):1212\u20135.","journal-title":"J Med Chem"},{"issue":"12","key":"2704_CR58","doi-asserted-by":"crossref","first-page":"7693","DOI":"10.1128\/AAC.00936-15","volume":"59","author":"D Pires","year":"2015","unstructured":"Pires D, Valente E, Simoes MF, Carmo N, Testa B, Constantino L, et al. Esters of Pyrazinoic acid are active against pyrazinamide-resistant strains of mycobacterium tuberculosis and other naturally resistant mycobacteria in vitro and ex vivo within macrophages. Antimicrob Agents Chemother. 2015;59(12):7693\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2704_CR59","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1021\/id500028m","volume":"1","author":"LE Via","year":"2015","unstructured":"Via LE, Savic R, Weiner DM, Zimmerman MD, Prideaux B, Irwin SM, et al. Host-mediated bioactivation of pyrazinamide: implications for efficacy, resistance, and Therapeutic Alternatives. ACS Infect Dis. 2015;1(5):203\u201314.","journal-title":"ACS Infect Dis"},{"issue":"7","key":"2704_CR60","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1128\/AAC.03085-15","volume":"60","author":"JP Lanoix","year":"2016","unstructured":"Lanoix JP, Tasneen R, O'Brien P, Sarathy J, Safi H, Pinn M, et al. High systemic exposure of Pyrazinoic acid has limited Antituberculosis activity in murine and rabbit models of tuberculosis. Antimicrob Agents Chemother. 2016;60(7):4197\u2013205.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2704_CR61","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/imr.12252","volume":"264","author":"A Lenaerts","year":"2015","unstructured":"Lenaerts A, Barry CE 3rd, Dartois V. Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses. Immunol Rev. 2015;264(1):288\u2013307.","journal-title":"Immunol Rev"},{"issue":"5","key":"2704_CR62","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1128\/AAC.01521-09","volume":"54","author":"DJ Ordway","year":"2010","unstructured":"Ordway DJ, Shanley CA, Caraway ML, Orme EA, Bucy DS, Hascall-Dove L, et al. Evaluation of standard chemotherapy in the Guinea pig model of tuberculosis. Antimicrob Agents Chemother. 2010;54(5):1820\u201333.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2704_CR63","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1128\/AAC.00978-10","volume":"55","author":"S Shang","year":"2011","unstructured":"Shang S, Shanley CA, Caraway ML, Orme EA, Henao-Tamayo M, Hascall-Dove L, et al. Activities of TMC207, rifampin, and pyrazinamide against mycobacterium tuberculosis infection in Guinea pigs. Antimicrob Agents Chemother. 2011;55(1):124\u201331.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"2704_CR64","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1128\/AAC.00276-07","volume":"51","author":"AJ Lenaerts","year":"2007","unstructured":"Lenaerts AJ, Hoff D, Aly S, Ehlers S, Andries K, Cantarero L, et al. Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910. Antimicrob Agents Chemother. 2007;51(9):3338\u201345.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2704_CR65","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/jps.20916","volume":"96","author":"AJ Hickey","year":"2007","unstructured":"Hickey AJ, Mansour HM, Telko MJ, Xu Z, Smyth HD, Mulder T, et al. Physical characterization of component particles included in dry powder inhalers. I. Strategy review and static characteristics. J Pharm Sci. 2007;96(5):1282\u2013301.","journal-title":"J Pharm Sci"},{"issue":"5","key":"2704_CR66","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/jps.20943","volume":"96","author":"AJ Hickey","year":"2007","unstructured":"Hickey AJ, Mansour HM, Telko MJ, Xu Z, Smyth HD, Mulder T, et al. Physical characterization of component particles included in dry powder inhalers. II Dynamic characteristics. J Pharm Sci. 2007;96(5):1302\u201319.","journal-title":"J Pharm Sci"},{"key":"2704_CR67","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/9781118943182.ch13","volume-title":"Drug delivery systems for tuberculosis prevention and treatment","author":"SC Das","year":"2016","unstructured":"Das SC, Stewart PJ. Understanding the respiratory delivery of high dose anti-tubercular drugs. In: Hickey AJ, Misra A, Fourie PB, editors. Drug delivery systems for tuberculosis prevention and treatment. New York: John Wiley and Sons; 2016. p. 258\u201374."},{"issue":"3","key":"2704_CR68","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejps.2005.11.013","volume":"28","author":"AH de Boer","year":"2006","unstructured":"de Boer AH, Hagedoorn P, Westerman EM, Le Brun PP, Heijerman HG, Frijlink HW. Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer) for high powder doses. Eur J Pharmaceut Sci : Off J Eur Fed Pharmaceut Sci. 2006;28(3):171\u20138.","journal-title":"Eur J Pharmaceut Sci : Off J Eur Fed Pharmaceut Sci"},{"issue":"1","key":"2704_CR69","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ijpharm.2018.07.008","volume":"548","author":"I Sibum","year":"2018","unstructured":"Sibum I, Hagedoorn P, de Boer AH, Frijlink HW, Grasmeijer F. Challenges for pulmonary delivery of high powder doses. Int J Pharm. 2018;548(1):325\u201336.","journal-title":"Int J Pharm"},{"issue":"5","key":"2704_CR70","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3390\/pharmaceutics11050233","volume":"11","author":"Imco Sibum","year":"2019","unstructured":"Sibum I, Hagedoorn P, Frijlink HW, Grasmeijer F. Characterization and Formulation of Isoniazid for High-Dose Dry Powder Inhalation. Pharmaceutics. 2019;11(5).","journal-title":"Pharmaceutics"},{"issue":"11","key":"2704_CR71","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1002\/jps.23705","volume":"102","author":"AJ Hickey","year":"2013","unstructured":"Hickey AJ, Misra A, Fourie PB. Dry powder antibiotic aerosol product development: inhaled therapy for tuberculosis. J Pharm Sci. 2013;102(11):3900\u20137.","journal-title":"J Pharm Sci"},{"issue":"1","key":"2704_CR72","doi-asserted-by":"crossref","first-page":"e54587","DOI":"10.1371\/journal.pone.0054587","volume":"8","author":"A Pooran","year":"2013","unstructured":"Pooran A, Pieterson E, Davids M, Theron G, Dheda K. What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa? PLoS One. 2013;8(1):e54587.","journal-title":"PLoS One"},{"issue":"5","key":"2704_CR73","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jcf.2019.05.013","volume":"18","author":"Brandon Banaschewski","year":"2019","unstructured":"Banaschewski B, Verma D, Pennings LJ, Zimmerman M, Ye Q, Gadawa J, Dartois V, Ordway D, van Ingen J, Ufer S, Stapleton K, Hofmann T. Clofazimine inhalation suspension for the aerosol treatment of pulmonary nontuberculous mycobacterial infections. J Cystic Fibrosis : Off J Eur Cystic Fibrosis Soc 2019;18(5):714\u2013720.","journal-title":"Journal of Cystic Fibrosis"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-019-2704-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-019-2704-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-019-2704-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T19:22:06Z","timestamp":1603394526000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-019-2704-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,24]]},"references-count":73,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2704"],"URL":"https:\/\/doi.org\/10.1007\/s11095-019-2704-6","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,24]]},"assertion":[{"value":"10 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"166"}}